Thomas Andre's most recent trade in Medifast Inc was a trade of 11,168 Common Stock done . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Medifast Inc | Andrea B. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 11,168 | 24,017 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 13 Jun 2025 | 289 | 96,593 (0%) | 0% | 0 | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Sale of securities on an exchange or to another person at price $ 341.59 per share. | 19 Mar 2025 | 325 | 1,902 (0%) | 0% | 341.6 | 111,018 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 411 | 411 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 411 | 2,039 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 303 | 606 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 303 | 2,270 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 260 | 1,669 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 260 | 0 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.16 per share. | 10 Mar 2025 | 126 | 1,913 (0%) | 0% | 376.2 | 47,396 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.16 per share. | 10 Mar 2025 | 93 | 2,177 (0%) | 0% | 376.2 | 34,983 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.16 per share. | 10 Mar 2025 | 80 | 1,589 (0%) | 0% | 376.2 | 30,093 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 79 | 78 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 79 | 1,992 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 73 | 144 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 73 | 2,250 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 57 | 0 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 57 | 1,646 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.16 per share. | 10 Mar 2025 | 25 | 1,967 (0%) | 0% | 376.2 | 9,404 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.17 per share. | 10 Mar 2025 | 23 | 2,227 (0%) | 0% | 376.2 | 8,652 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.17 per share. | 10 Mar 2025 | 18 | 1,628 (0%) | 0% | 376.2 | 6,771 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 07 Mar 2025 | 220 | 96,304 (0%) | 0% | 0 | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 684 | 684 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 171 | 171 | - | - | Restricted Stock Unit | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Sale of securities on an exchange or to another person at price $ 51.79 per share. | 10 Feb 2025 | 7,100 | 96,084 (0%) | 0% | 51.8 | 367,709 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 11,287 | 103,184 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.71 per share. | 27 Dec 2024 | 2,730 | 91,897 (0%) | 0% | 56.7 | 154,818 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 06 Dec 2024 | 183 | 94,627 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 13 Sep 2024 | 173 | 94,444 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Andrea B. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 6,596 | 12,849 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 14 Jun 2024 | 176 | 94,271 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 04 Jun 2024 | 4,801 | 94,095 (0%) | 0% | 61.4 | 294,925 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 15 Mar 2024 | 157 | 98,896 (0%) | 0% | 0 | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 411 | 822 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 411 | 1,392 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 261 | 260 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 261 | 1,021 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 128 | 800 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 128 | 0 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 327.00 per share. | 10 Mar 2024 | 126 | 1,266 (0%) | 0% | 327 | 41,202 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 327.00 per share. | 10 Mar 2024 | 80 | 941 (0%) | 0% | 327 | 26,160 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 79 | 157 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 79 | 1,345 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 58 | 57 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 58 | 999 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 327.00 per share. | 10 Mar 2024 | 40 | 760 (0%) | 0% | 327 | 13,080 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 327.00 per share. | 10 Mar 2024 | 25 | 1,320 (0%) | 0% | 327 | 8,175 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 327.00 per share. | 10 Mar 2024 | 18 | 981 (0%) | 0% | 327 | 5,886 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 867 | 867 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 217 | 217 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 54,415 | 236,091 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 14.11 per share. | 17 Feb 2024 | 24,888 | 211,203 (1%) | 0% | 14.1 | 351,289 | Common Stock |
| KalVista Pharmaceuticals Inc | Andrew Crockett Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 20,834 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 62,500 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Andrew Thomas Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 6,944 | 48,612 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 5,805 | 52,245 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 14 Feb 2024 | 58,356 | 181,676 (1%) | 0% | 15.0 | 875,883 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 122,500 | 240,032 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 83,333 | 83,333 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Andrew Thomas Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 01 Feb 2024 | 9,300 | 118,232 (0%) | 0% | 16.2 | 150,428 | Common Stock |
| KalVista Pharmaceuticals Inc | Andrew Crockett Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.81 per share. | 01 Feb 2024 | 700 | 117,532 (0%) | 0% | 16.8 | 11,770 | Common Stock |
| Biomea Fusion Inc | Andrew Thomas Butler | Director, Chief Executive Officer, Ten Percent Owner | 17 Jan 2024 | 407,502 | 407,502 | - | - | Stock Option (Right to Buy) | ||
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 7,697 | 98,739 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | Chief Experience Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 2,131 | 91,042 (0%) | 0% | 0 | Common Stock | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 27 Dec 2023 | 30,000 | 127,532 (0%) | 0% | 12.0 | 360,453 | Common Stock |
| Kforce Inc. | Thomas G. Andrew | Chief Experience Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.84 per share. | 27 Dec 2023 | 3,105 | 88,911 (0%) | 0% | 67.8 | 210,643 | Common Stock |
| Kforce Inc. | G. Andrew Thomas | Chief Experience Officer | Other type of transaction at price $ 0.00 per share. | 15 Dec 2023 | 164 | 92,016 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Andrea B. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 69.42 per share. | 07 Nov 2023 | 50 | 6,253 (0%) | 0% | 69.4 | 3,471 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Sale of securities on an exchange or to another person at price $ 219.06 per share. | 25 Sep 2023 | 454 | 672 (0%) | 0% | 219.1 | 99,453 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Sale of securities on an exchange or to another person at price $ 220.50 per share. | 19 Sep 2023 | 175 | 1,126 (0%) | 0% | 220.5 | 38,587 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 33,582 | 161,632 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 20,833 | 0 | - | - | Performance Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 10.73 per share. | 17 Aug 2023 | 14,876 | 146,756 (0%) | 0% | 10.7 | 159,602 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 6,944 | 62,501 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 5,805 | 63,855 | - | - | Restricted Stock Unit | |
| Medifast Inc | Andrea B. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 89.68 per share. | 08 Aug 2023 | 38 | 6,202 (0%) | 0% | 89.7 | 3,408 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Other type of transaction at price $ 0.00 per share. | 16 Jun 2023 | 183 | 91,825 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Andrea B. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 3,118 | 6,164 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Andrea B. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 94.42 per share. | 09 May 2023 | 12 | 3,046 (0%) | 0% | 94.4 | 1,133 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 261 | 521 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 261 | 1,341 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 209 | 0 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 209 | 1,055 (0%) | 0% | - | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 183 | 91,642 (0%) | 0% | 0 | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 129 | 128 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 129 | 1,120 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 213.64 per share. | 10 Mar 2023 | 80 | 1,261 (0%) | 0% | 213.6 | 17,091 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 213.64 per share. | 10 Mar 2023 | 64 | 991 (0%) | 0% | 213.6 | 13,673 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 58 | 1,319 (0%) | 0% | - | Common Stock | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 58 | 115 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 213.65 per share. | 10 Mar 2023 | 40 | 1,080 (0%) | 0% | 213.7 | 8,546 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 213.67 per share. | 10 Mar 2023 | 18 | 1,301 (0%) | 0% | 213.7 | 3,846 | Common Stock |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 942 | 942 | - | - | Restricted Stock Unit | |
| Kadant, Inc. | Thomas Andrew Blanchard | Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 236 | 236 | - | - | Restricted Stock Unit | |
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Sale of securities on an exchange or to another person at price $ 61.83 per share. | 24 Feb 2023 | 20,000 | 91,459 (0%) | 0% | 61.8 | 1,236,600 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 6,944 | 76,390 | - | - | Restricted Stock Unit | |
| Medifast Inc | Andrea B. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 123.33 per share. | 07 Feb 2023 | 9 | 3,033 (0%) | 0% | 123.3 | 1,110 | Common Stock |
| Biomea Fusion Inc | Thomas Andrew Butler | Director, Chief Executive Officer, Ten Percent Owner | 06 Jan 2023 | 354,350 | 354,350 | - | - | Stock Option (Right to Buy) | ||
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 9,849 | 111,459 (0%) | 0% | 0 | Common Stock | |
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.97 per share. | 27 Dec 2022 | 4,310 | 101,610 (0%) | 0% | 55.0 | 236,921 | Common Stock |
| Kforce Inc. | Andrew G. Thomas | CHIEF MARKETING OFFICER | Other type of transaction at price $ 0.00 per share. | 09 Dec 2022 | 221 | 105,920 (0%) | 0% | 0 | Common Stock |